Download the Protocol

Retatrutide

Retatrutide is a next-generation weight management and metabolic peptide that targets three hormone pathways at once. It acts on GLP-1, GIP, and glucagon receptors to reduce appetite, improve blood sugar control, and increase energy use. Research shows it may produce some of the strongest weight loss and metabolic improvements seen so far among incretin-based therapies.

Description

• Retatrutide (LY3437943) is a triple agonist activating GLP-1, GIP, and glucagon receptors.
• Developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and fatty liver disease.
• Designed to provide synergistic benefits in appetite control, fat metabolism, and energy balance.

How It Works

• GLP-1 activation: increases satiety, slows digestion, and boosts insulin release.
• GIP activation: enhances insulin secretion and metabolic efficiency.
• Glucagon activation: increases energy expenditure and fat oxidation.
• Combined, these mechanisms produce sustained fat loss and improved metabolic health.

Documented Effects

• Phase 2 trials showed average body weight reductions of up to 24% at 48 weeks.
• Improves glucose control, lipid profiles, and liver fat content.
• Most common side effects: nausea, vomiting, mild fatigue, and gastrointestinal upset.

Theoretical Effects

• Expected to outperform dual-agonists like tirzepatide in long-term metabolic benefits.
• Potential to support cardiovascular and hepatic health through fat mobilization.
• Still under clinical investigation for diabetes prevention and metabolic optimization.

Pharmacokinetics

• Half-life: ~6–7 days, suitable for once-weekly administration.
• Peak effect: 24–48 hours post-injection.
• Elimination: Slow clearance via renal and hepatic pathways.

Reconstitution

• Use bacteriostatic water to dissolve the lyophilized powder.
• Example vial: 10 mg of Retatrutide
• Choose reconstitution volume based on preference:
  • 1 mL → 10 mg/mL → 1 mg per 10 units
  • 2 mL → 5 mg/mL → 500 mcg per 10 units
• Swirl gently; do not shake or heat.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Research Reference)

Typical Starting Dose

• 500 mcg to 1 mg subcutaneous (SC) once weekly in early-stage research dosing.
• Begin low to limit gastrointestinal effects; titrate upward every 2–4 weeks.

Typical clinical titration

This is the pattern used in studies and by obesity specialists:



• Weeks 1–4: 0.5 mg weekly
• Weeks 5–8: 1 mg weekly
• Weeks 9–12: 1.5 mg weekly
• Optional after 12–16 weeks: 2 mg weekly (only if needed and tolerated)

Common Therapeutic Range

• 4–8 mg SC once weekly, depending on tolerance and study design.
• Incremental increases used to maintain adherence and minimize side effects.

Maximum Weekly Dose

• Clinical testing has reached 12 mg once weekly.
• Higher doses lack published safety and tolerability data.

Standard Cycle Length

• Used as a continuous therapy for 48–72 weeks in metabolic research.
• Not structured as a short-term cycle; effects build gradually.

Clinical Notes

• Administered subcutaneously, typically once weekly due to its long half-life and prolonged receptor engagement.
• Targets GLP-1, GIP, and glucagon receptors simultaneously, producing strong appetite suppression and metabolic effects.
• Best injected in the abdomen, thigh, or upper arm; rotate sites weekly to prevent irritation.
• Most common early effects include nausea, decreased appetite, fullness, and mild fatigue as gastric emptying slows.
• Start at lower doses when possible to reduce gastrointestinal discomfort during the first 1–3 weeks.
• Avoid large, carbohydrate-heavy meals around injection day to minimize nausea.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Primary side effects: nausea, vomiting, and delayed gastric emptying.
• Contraindicated in individuals with MEN2 or a history of medullary thyroid carcinoma.
• Use caution when combining with other incretin or glucose-lowering agents.
• Long-term cardiovascular outcomes still under investigation.